Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2007;157(13-14):295-300.

doi: 10.1007/s10354-007-0427-5.

Affiliations

Randomized Controlled Trial

Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial

Andrey Scripnikov et al. Wien Med Wochenschr. 2007.

Abstract

In a randomised, double-blind, 22-week trial 400 patients with dementia associated with neuropsychiatric features were treated with Ginkgo biloba extract EGb 761 (240 mg/day) or placebo. Patients with probable Alzheimer's disease, possible Alzheimer's disease with cerebrovascular disease or vascular dementia were eligible if they scored 9 to 23 on the SKT cognitive test battery and at least 5 on the Neuropsychiatric Inventory (NPI). EGb 761 was significantly superior to placebo with respect to the primary (SKT test battery) and all secondary outcome variables. The mean composite score (frequency x severity) and the mean caregiver distress score of the NPI dropped from 21.3 to 14.7 and 13.5 to 8.7, respectively, in the EGb 761-treated patients, but increased from 21.6 to 24.1 and 13.4 to 13.9, respectively, under placebo (p < 0.001). The largest drug-placebo differences in favour of EGb 761 were found for apathy/indifference, anxiety, irritability/lability, depression/dysphoria and sleep/nighttime behaviour.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Curr Alzheimer Res. 2005 Dec;2(5):541-51 - PubMed
    1. Int J Geriatr Psychiatry. 2006 May;21(5):449-59 - PubMed
    1. Arzneimittelforschung. 2007;57(1):4-11 - PubMed
    1. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12197-202 - PubMed
    1. J Am Geriatr Soc. 1974 Mar;22(3):107-13 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources